Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/09/24
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin TestBusiness Wire • 01/29/24
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference CallBusiness Wire • 01/23/24
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector ManufacturingBusiness Wire • 01/16/24
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing CollaborationBusiness Wire • 12/18/23
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug ScreeningBusiness Wire • 12/12/23
Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/08/23
Charles River® and S&P Global Market Intelligence Announce Collaboration to Streamline Primary Issuance in Charles River® IMSBusiness Wire • 11/28/23
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing CollaborationBusiness Wire • 11/28/23
Charles River Laboratories: Mr. Market Went From Overvaluation To UndervaluationSeeking Alpha • 11/26/23
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular ProductsBusiness Wire • 11/16/23